| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Updated results from the HIMALAYA Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) plus IMJUDO®(tremelimumab-actl...
First immunotherapy regimen before and after surgery to demonstrate statistically significant and clinically meaningful overall...
Daiichi Sankyo and AstraZeneca's ENHERTU achieved a 61.6% progression-free survival rate at one year in patients with activ...
https://www.moffitt.org/newsroom/news-releases/moffitt-cancer-center-announces-strategic-collaboration-with-astrazeneca-to-acce...
Erste Group analyst Hans Engel upgrades AstraZeneca (NASDAQ:AZN) from Hold to Buy.
The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 monthsBOSTON and ...
- Reuters
Chinese authorities have detained AstraZeneca employees amid a probe into potential data privacy breaches and unlicensed drug i...
AstraZeneca shared detailed results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan for non-small cell lung can...
